Other products
Purevax FeLV
Active substance
ATC code
Species
Cats.
Indications
Active immunisation of cats of 8 weeks of age or older against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.
Onset of immunity: 2 weeks after primary vaccination course.
Duration of immunity: 1 year after the last vaccination.
Dose to be administered and administration route
Subcutaneous use.
Administer one dose of 1 ml or 0.5 ml (depending on the presentation chosen) according to the following schedule:
| Basic vaccination: | first injection: from 8 weeks of age, |
| second injection: 3 to 5 weeks later. | |
| Revaccination: | annual |
Adverse reactions
Cats:
|
Very common (>1 animal / 10 animals treated): |
Injection site nodule.1 Lethargy, hyperthermia.2 |
|
Very rare (<1 animal / 10 000 animals treated, including isolated reports): |
Anorexia, emesis. Hypersensitivity reaction, anaphylaxis.3 |
1Small (< 2 cm) , regresses within 1 to 4 weeks.
2Lasting usually for 1 day, exceptionally for 2 days.
3If such reactions occur, appropriate treatment is recommended.
May evolve to a more severe condition (anaphylaxis). If such reactions occur, appropriate treatment is recommended.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Dispensing
POM-V - Prescription Only Medicine – VeterinarianSUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Purevax FeLV suspension for injection
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Per dose of I ml or 0.5 ml:
Active substances:
FeLV recombinant Canaryypox virus (vCP97) ≥ 107.2 CCID501
1cell culture infective dose 50% Excipients:
|
Qualitative composition of excipients and other constituents |
|
Potassium chloride |
|
Sodium chloride |
|
Potassium dihydrogen phosphate |
|
Disodium phosphate dihydrate |
|
Magnesium chloride hexahydrate |
|
Calcium chloride dihydrate |
|
Water for injections |
Clear colourless liquid with presence of cell debris in suspension.
3. CLINICAL INFORMATION
3.1 Target species
Cats.
3.2 Indications for use for each target species
Active immunisation of cats of 8 weeks of age or older against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.
Onset of immunity: 2 weeks after primary vaccination course. Duration of immunity: 1 year after the last vaccination.
3.3 Contraindications
None.
3.4 Special warnings
Vaccinate healthy animals only.
3.5 Special precautions for use
Special precautions for safe use in the target species:
It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination.
Vaccination of FeLV positive cats is of no benefit.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Special precautions for the protection of the environment: Not applicable.
3.6 Adverse events Cats:
|
Very common (>1 animal / 10 animals treated): |
Injection site nodule.1 Lethargy, hyperthermia.2 |
|
Very rare (<1 animal / 10 000 animals treated, including isolated reports): |
Anorexia, emesis. Hypersensitivity reaction, anaphylaxis.3 |
1Small (< 2 cm) , regresses within 1 to 4 weeks.
2Lasting usually for 1 day, exceptionally for 2 days.
3If such reactions occur, appropriate treatment is recommended.
May evolve to a more severe condition (anaphylaxis). If such reactions occur, appropriate treatment is recommended.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
3.7 Use during pregnancy, lactation or lay
Do not use during the whole pregnancy and lactation.
3.8 Interaction with other medicinal products and other forms of interaction
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Boehringer Ingelheim non-adjuvanted vaccine range (various combinations of feline viral rhinotracheitis, calicivirosis, panleukopenia and chlamydiosis components) and/or administered the same day but not mixed with Boehringer Ingelheim adjuvanted vaccine against rabies.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.
3.9 Administration routes and dosage
Subcutaneous use.
Administer one dose of 1 ml or 0.5 ml (depending on the presentation chosen) according to the following schedule:
Basic vaccination: first injection: from 8 weeks of age, second injection: 3 to 5 weeks later.
Revaccination: annual
3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)
No adverse events other than those already mentioned in section 3.6 “Adverse events” have been observed.
3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance
Not applicable.
3.12 Withdrawal periods
Not applicable
4. IMMUNOLOGICAL INFORMATION
4.1 ATCvet code: QI06AD07
The vaccine strain is a recombinant canarypox virus expressing the env and gag genes of FeLV-A. Under field conditions, only sub-group A is infective and immunisation against sub-group A provides full protection against A, B and C. After inoculation, the virus expresses the protective proteins, but does not replicate in the cat. As a consequence, the vaccine induces an immune status against feline leukaemia virus.
5. PHARMACEUTICAL PARTICULARS
5.1 Major incompatibilities
Do not mix with any other veterinary medical product, except those mentioned in section 3.8 above.
5.2 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 2 years. Shelf life after first opening the immediate packaging: use immediately.
5.3 Special precautions for storage
Store and transport refrigerated (2 °C – 8 °C).
Protect from light. Do not freeze.
5.4 Nature and composition of immediate packaging
Type I glass bottle containing 1 ml or 0.5 ml of vaccine, closed with a butyl elastomer closure and sealed with an aluminium cap.
Plastic box containing 10, 20 or 50 bottles of 1 ml of vaccine.
Plastic box containing 10, 20 or 50 bottles of 0.5 ml of vaccine.
Not all pack sizes may be marketed.
5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Medicines should not be disposed of via wastewater or household waste.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.
6. NAME OF THE MARKETING AUTHORISATION HOLDER
Boehringer Ingelheim Vetmedica GmbH
7. MARKETING AUTHORISATION NUMBER
Vm 61700/5066
8. DATE OF FIRST AUTHORISATION
13 April 2000
9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS
January 2025
10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT
Veterinary medicinal product subject to prescription.
Find more product information by searching for the ‘Product Information Database’ on www.gov.uk.
Approved 03 June 2025
| Art. Nr. | 04491/5050 |
|---|---|
| GTIN | • • • • • • • • • 7973 |
